Resource Logo
NLM AIDSLINE

Acetylator phenotype prevalence in HIV-infected patients without previous trimethoprim-sulfamethoxazole hypersensitivity [letter]




 

Biomed Pharmacother. 1999 Jun;53(5-6):286-7. Unique Identifier :

This trial was conducted to study the frequency of the slow acetylator phenotype in asymptomatic HIV patients having no previous reaction to sulfa-drugs, and to compare this frequency with the frequency found in healthy controls. Results show that HIV alone is not capable of modifying the acetylator phenotype; the prevalence of slow acetylator phenotype is the same in immune competent subjects and HIV-positive patients. It is more common in HIV-positive patients with a CD4+ lymphocyte count of less than 200 mm-3.

CLINICAL TRIAL LETTER JOURNAL ARTICLE Acetylation Adult Anti-Infective Agents/*ADVERSE EFFECTS Drug Hypersensitivity/EPIDEMIOLOGY/*GENETICS Female Human HIV Infections/*GENETICS/METABOLISM HIV Seropositivity Kinetics Male Phenotype Support, Non-U.S. Gov't Trimethoprim-Sulfamethoxazole Combination/*ADVERSE EFFECTS



 




Information in this article was accurate in December 30, 1999. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.